Drugs / SJCAR19
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03573700 | Jul 2018 → Jul 2023 overdue | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SJCAR19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03573700 ↗ |
| Action | Deplete | “engineer them to more effectively kill cancer cells.” NCT03573700 ↗ |
| Route | Intravenous | “Given IV” NCT03573700 ↗ |
| Target | CD19 | “CD19- specific CAR engineered autologous T-cells (SJCAR19 product)” NCT03573700 ↗ |